# PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

> **NCT06665100** · PHASE2 · RECRUITING · sponsor: **Pulmotect, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Hematologic Malignancies
- Hematopoietic Stem Cell Transplant (HSCT)

## Interventions

- **DRUG:** PUL-042
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06665100
- **Lead sponsor:** Pulmotect, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-27
- **Primary completion:** 2027-04
- **Final completion:** 2027-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06665100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06665100, "PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06665100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*